Navigation Links
UT Southwestern researchers find drug-coated stents less risky for heart bypass patients
Date:1/21/2009

DALLAS Jan. 22, 2009 Coronary bypass surgery may carry less risk of serious complications if stents coated with a drug that suppresses cell growth are used in the procedure rather than bare-metal stents, UT Southwestern Medical Center researchers and colleagues have found.

The study, appearing online and in an upcoming issue of The Journal of the American College of Cardiology, is the first large, multicenter trial comparing two types of commonly used stents. Stents are small mesh tubes that reinforce the walls of blocked blood vessels. In this study, stents were used to treat blockages in diseased coronary arteries.

In bypass surgery, grafts are taken from the saphenous vein in the patient's thigh and sewn to the coronary arteries to help improve blood flow to the heart, relieve severe chest pain and reduce the risk of heart attacks from blocked arteries. Years after surgery, those grafts may develop blockages inside the graft that are challenging to treat because of high rates of recurrence.

"We wanted to see if one type of stent was superior in reducing the incidence of re-narrowing of the vein graft," said Dr. Emmanouil Brilakis, assistant professor of internal medicine at UT Southwestern and lead author of the study. "Stented vein grafts have a very high risk of re-narrowing sometimes up to 50 percent when bare metal stents are used.

"Drug-eluting stents could provide a solution to this problem, but limited clinical results have been reported to date. The drug-eluting stents examined in our study are coated with a medication called paclitaxel, which inhibits cell growth."

The drug coating is contained on a polymer that covers the surface of the stents and eventually elutes, or washes out of the stent, over a period of several months or years.

In the study, researchers examined 80 patients, roughly half of whom had vein grafts with drug-eluting stents and the other half who had the same proce
'/>"/>

Contact: Katherine Morales
katherine.morales@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

1

GOOD

Page: 1 2

Related medicine news :

1. UT Southwestern University Hospitals transplant program recognized for increasing organ donor rates
2. Childhood anxiety disorders can and should be treated, according to UT Southwestern national expert
3. Interferon needed for cells to remember how to defeat a virus, UT Southwestern researchers report
4. UT Southwestern researchers develop new strategy for broad spectrum anti-viral drugs
5. Cancer requires support from immune system to develop, UT Southwestern researchers report
6. Vaginal/Caesarean combo delivery of twins safe, UT Southwestern-led research finds
7. Steroids aid recovery from pneumonia, UT Southwestern researchers say
8. Superbug breast infections controllable in nursing mothers, UT Southwestern researchers find
9. UT Southwestern scientists discover leptin can also aid type 1 diabetics
10. Tiny molecule helps control blood-vessel development, UT Southwestern researchers find
11. UT Southwestern launches study of surgical option for treating diabetic and other neuropathies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2010)... SEATTLE - The incidence of advanced breast cancer diagnosis ... higher compared to white women between 1992 and 2004, ... Cancer Research Center. In addition, the disparity in the ... time period as rates fell among whites but increased ... in the inaugural issue of Springer,s journal Hormones ...
(Date:2/9/2010)... association between television viewing and childhood obesity is directly ... foods, according to a new UCLA School of Public ... Public Health . , The study, conducted by Frederick ... to break down the types of television children watch ... exert different effects on obesity. , The researchers gathered ...
(Date:2/9/2010)... - Overexpression of low-molecular-weight (LMW-E) forms of the ... ineffective among women with estrogen-receptor-positive (ER+) breast cancers, ... Anderson Cancer Center report in Clinical Cancer ... led by Khandan Keyomarsi, Ph.D., professor in M. ... the Hubert L. and Olive Stringer Professor in ...
(Date:2/9/2010)... whacked-out on powerful prescription drugs to treat anxiety disorders. ... sufferer shows natural ways to find relief from constant worry. ... ... -- Over 40 million Americans suffer from anxiety disorders, a ... . Typical anxiety treatment includes prescribing powerful antidepressants or ...
(Date:2/9/2010)... fluoroscopes may increase cancer risk, officials say , ... U.S. Food and Drug Administration unveiled a plan ... of increasingly widespread imaging procedures: computed tomography (CT), ... imaging techniques are the largest contributors to total ... radiation doses than other imaging procedures, such as ...
Breaking Medicine News(10 mins):Health News:Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S. 2Health News:Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S. 3Health News:Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S. 4Health News:Childhood obesity: It's not the amount of TV, it's the number of junk food commercials 2Health News:Low forms of cyclin E reduce breast cancer drug's effectiveness 2Health News:Low forms of cyclin E reduce breast cancer drug's effectiveness 3Health News:Social Anxiety and Panic - Alternative Treatment to Drugs and Therapy 2Health News:FDA Seeks Reduction in Radiation From Medical Scans 2Health News:FDA Seeks Reduction in Radiation From Medical Scans 3
... Company (NYSE: PG ) announced that its Board of ... ($0.35) to forty,cents ($0.40) per share on its Common Stock ... A Preferred Stock of the company, payable on or,after May ... business on,April 18, 2008. This represents a 14% increase compared ...
... To Close Derivative Lawsuit Filed in ... ... April 8, 2008 KV Pharmaceutical,Company (NYSE: KVa/KVb), a fully ... branded and generic/non-branded prescription pharmaceutical,products, announced today that it has ...
... equine estrogen, a commonly prescribed form of estrogen, had ... of benign breast disease as women who took a ... April 8 in the Journal of the National ... estrogen on the risk of developing benign proliferative breast ...
... looking at the spines of hundreds of Finnish twins? If ... Spine Study, you find compelling proof that back pain problems ... , The findings of the Twin Spine Study, an ongoing ... paradigm shift in the way disc degeneration is understood. Last ...
... the worlds busiest ports and shipping regions may be ... study showing that industrial and shipping pollution is exacerbated ... , In a paper published in this weeks advance ... of researchers that included University of Calgary chemistry professor ...
... over $7 million to date in its childhood ... ... In recognition of,national Public Health Week, Anthem Blue Cross, in collaboration ... Index (BMI) training and promotion workshops in Pasadena, San Jose,and Bakersfield, ...
Other Medicine News:Health News:KV Pharmaceutical Company Announces Proposed Settlement in Principle of Derivative Shareholder Litigation 2Health News:KV Pharmaceutical Company Announces Proposed Settlement in Principle of Derivative Shareholder Litigation 3Health News:Estrogen therapy increases benign breast disease risk 2Health News:Award-winning study says back pain may be in your genes 2Health News:Sea salt worsens coastal air pollution: study 2Health News:Anthem Blue Cross Tackles Childhood Obesity in California Through Free BMI Workshops for Pediatric and Family Medicine Health Care Providers 2Health News:Anthem Blue Cross Tackles Childhood Obesity in California Through Free BMI Workshops for Pediatric and Family Medicine Health Care Providers 3
(Date:2/9/2010)... Feb. 9 Takeda Global ... announced today that it has initiated a trial ... pump inhibitors (PPIs) affect the pharmacokinetics and pharmacodynamics ... has been evaluating all published data and communications ... regarding the potential risks associated with concomitant use ...
(Date:2/9/2010)... 9 DATATRAK International, Inc. (OTCQX: ... global eClinical solutions for the clinical trials industry, ... a CRO Connect Partner, will co-sponsor a seminar ... eClinical solutions for the clinical trials industry. The ... decipher the challenges, costs and obstacles customarily encountered ...
(Date:2/9/2010)... Switzerland , February 9 /PRNewswire/ ... group of companies with,a focus on the ... medical,needs, today announced the signature of an ... manufacture and commercialisation of Debio 025,(alisporivir), a ... anti-hepatitis C virus (HCV) effect. The product ...
Breaking Medicine Technology:Takeda Announces Initiation of Trial to Study the Concomitant Use of Dexlansoprazole and Other Proton Pump Inhibitors with Plavix(R) (clopidogrel bisulfate) 2Takeda Announces Initiation of Trial to Study the Concomitant Use of Dexlansoprazole and Other Proton Pump Inhibitors with Plavix(R) (clopidogrel bisulfate) 3Takeda Announces Initiation of Trial to Study the Concomitant Use of Dexlansoprazole and Other Proton Pump Inhibitors with Plavix(R) (clopidogrel bisulfate) 4DATATRAK International and PFC Pharma Focus to Co-Sponsor eClinical Solutions Seminar in Tel Aviv 2DATATRAK International and PFC Pharma Focus to Co-Sponsor eClinical Solutions Seminar in Tel Aviv 3DATATRAK International and PFC Pharma Focus to Co-Sponsor eClinical Solutions Seminar in Tel Aviv 4Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025 2Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025 3Reimbursement Difficulties With TranS1s AxiaLIF and NuVasives XLIF Have Sceptics Talking 7074 1Reimbursement Difficulties With TranS1s AxiaLIF and NuVasives XLIF Have Sceptics Talking 7074 2Reimbursement Difficulties With TranS1s AxiaLIF and NuVasives XLIF Have Sceptics Talking 7074 3Accuray Incorporated to Present at 28th Annual J P Morgan Healthcare Conference 7070 1Accuray Incorporated to Present at 28th Annual J P Morgan Healthcare Conference 7070 2HealthWarehouse com Inc Secures 241 Million in Debt Financing 7066 1HealthWarehouse com Inc Secures 241 Million in Debt Financing 7066 2
... therapy reduced risk of breast cancer return or death ... III data to substantiate anticancer effect of Zometa- Zometa ... bone complications due to bone metastases, with more than ... /PRNewswire/ -- A newly published study in ...
... ATLANTA, Feb. 10 Food retailers concerned about pathogens ... coli in their perishable departments can now outsource ... operates food safety and sanitation programs throughout the United ... food safety, Chemstar has expanded its sanitation services to ...
Other Medicine Technology:Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports 2Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports 3Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports 4Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports 5Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports 6Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports 7Chemstar Corporation Offers Comprehensive Deep Cleaning Programs to Combat Salmonella, Listeria, and E. coli in Retail Supermarkets 2
... were designed primarily for schools and laboratories where ... not required. They are constructed to the same ... but have larger tip openings for faster delivery. ... that accuracy tolerances are twice those specified for ...
1000L...
Inquire...
... ergonomics, and value!, Comfortable feel ... non-slip, contoured handle , Finer control ... spring action , Completely autoclavable for ... need for recalibration , Easy-to-read precision ...
Medicine Products: